Transcode Therapeutics, Inc. financial data

Symbol
RNAZ on Nasdaq
Location
6 Liberty Square, #2382, Boston, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 350 % +115%
Debt-to-equity 103 % -20.2%
Return On Equity -612 % -2.46%
Return On Assets -301 % -15.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 834K shares -95.2%
Common Stock, Shares, Outstanding 834K shares -88.5%
Entity Public Float 7.3M USD +65.9%
Common Stock, Value, Issued 84 USD -88.4%
Weighted Average Number of Shares Outstanding, Basic 834K shares +10825%
Weighted Average Number of Shares Outstanding, Diluted 834K shares +10825%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.65M USD -16.4%
General and Administrative Expense 5M USD -20.2%
Operating Income (Loss) -14.7M USD +17.7%
Nonoperating Income (Expense) -9.95M USD -10440%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -24.6M USD -37.4%
Earnings Per Share, Basic 646 USD/shares +99.2%
Earnings Per Share, Diluted 646 USD/shares +99.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.37M USD +120%
Assets, Current 8.24M USD +87.9%
Property, Plant and Equipment, Net 24.7K USD -61.8%
Operating Lease, Right-of-Use Asset 37.7K USD -92.2%
Assets 8.27M USD +71.3%
Contract with Customer, Liability, Current 0 USD
Liabilities, Current 1.56M USD -55.3%
Operating Lease, Liability, Noncurrent 38.3K USD
Liabilities 2.12M USD -39.5%
Retained Earnings (Accumulated Deficit) -79.6M USD -44.8%
Stockholders' Equity Attributable to Parent 6.15M USD +365%
Liabilities and Equity 8.27M USD +71.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.1M USD +21.3%
Net Cash Provided by (Used in) Financing Activities 8.85M USD +45.5%
Net Cash Provided by (Used in) Investing Activities -3.84K USD +70.3%
Common Stock, Shares Authorized 290M shares 0%
Common Stock, Shares, Issued 834K shares -88.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 5.76M USD +168%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.37M USD +120%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.65K USD -31.9%
Deferred Tax Assets, Valuation Allowance 16.1M USD +27.4%
Deferred Tax Assets, Gross 16.1M USD +27.4%
Operating Lease, Liability 38.3K USD -91.5%
Depreciation 13.4K USD -58.2%
Payments to Acquire Property, Plant, and Equipment 3.84K USD -70.3%
Lessee, Operating Lease, Liability, to be Paid 38.3K USD -91.7%
Property, Plant and Equipment, Gross 362K USD -7.66%
Operating Lease, Liability, Current 38.3K USD -90.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38.3K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 38.3K USD -90.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.03K USD -93.2%
Deferred Tax Assets, Operating Loss Carryforwards 8.89M USD +51.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 228K USD -35.4%
Operating Lease, Payments 332K USD -18.4%
Additional Paid in Capital 85.7M USD +52.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 53.3K USD -58.2%
Interest Expense 17.2K USD -67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%